Ginns E I, Tegelaers F P, Barneveld R, Galjaard H, Reuser A J, Brady R O, Tager J M, Barranger J A
Clin Chim Acta. 1983 Jul 15;131(3):283-7. doi: 10.1016/0009-8981(83)90097-9.
Discrimination between the three clinical subtypes of Gaucher's disease based on the molecular forms of beta-glucocerebrosidase detected by monoclonal antibody is described. In normal fibroblast extracts, cross-reacting material (CRM) to human placental glucocerebrosidase is detected at Mr approximately equal to 63 000, 61 000 and 56 000. In Type 1 Gaucher's disease, the major fibroblast CRM has a Mr approximately equal to 56 000,, with less CRM seen at 61 000 and 56 000. Type 3 fibroblast extracts have a single CRM form at Mr approximately equal to 63 000. No CRM is found in Type 2 Gaucher's disease fibroblasts with monoclonal antiglucocerebrosidase antibody 8E4.
本文描述了基于单克隆抗体检测到的β-葡萄糖脑苷脂酶分子形式对戈谢病三种临床亚型的鉴别。在正常成纤维细胞提取物中,可检测到与人类胎盘葡萄糖脑苷脂酶发生交叉反应的物质(CRM),其分子量约为63000、61000和56000。在1型戈谢病中,主要的成纤维细胞CRM分子量约为56000,在61000和56000处可见较少的CRM。3型成纤维细胞提取物具有单一的CRM形式,分子量约为63000。用抗葡萄糖脑苷脂酶单克隆抗体8E4在2型戈谢病成纤维细胞中未发现CRM。